Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Particle Sciences
BETHLEHEM, Pa., Oct. 10, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO) , has completed the clinical trial manufacturing of vaginal rings with a unique architecture, essentially a powdered filled tube. Designed to deliver the pro-drug tenofovir disoproxil fumarate for 30 days, the device is aimed at HIV prevention and joins several other microbicide delivery approaches under development. The ring provided complete protection in macaques against the related virus, SHIV, in studies conducted at the Center for Disease Control. According to Mark Mitchnick MD, Particle Sciences' CEO, "Particle Sciences focuses on formulation design and manufacturing. Given the issues our clients face, the dosage forms we work with often require a high level of engineering and reducing complex formulations to commercially viable products is something we frequently do. In this case, the product is a drug eluting device funded under an NIH grant led by Betsy Herold, M.D., Professor and Director, Translational Prevention Research Center at Albert Einstein College of Medicine. The product itself was designed by Patrick Kiser, PhD, Associate Professor of Biomedical Engineering at Northwestern University." Mitchnick added, "We have worked very hard to make Particle Sciences the go-to resource for complex formulation and manufacturing. This year alone, in addition to this product, we have manufactured sterile nano-dispersions, IV emulsions, IM sustained release suspensions and a host of other products, the majority of which were developed at Particle Sciences. We have a long history with prevention technologies and were delighted to be able to work on this one."
Particle Sciences is an integrated pharmaceutical CDMO. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email firstname.lastname@example.org or contact us at (610) 861- 4701 for information.
Contact: Maureen Grieco
©2012 PR Newswire. All Rights Reserved.